Overview

Ipilimumab + Temozolomide in Metastatic Melanoma

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied. Researchers would also like to study how this therapy affects the levels of certain chemicals in the blood that are related to your immune system.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Dacarbazine
Ipilimumab
Temozolomide